Centessa Pharmaceuticals Future Growth
Future criteria checks 0/6
Centessa Pharmaceuticals's earnings are forecast to decline at 2.1% per annum while its annual revenue is expected to grow at 81.8% per year. EPS is expected to grow by 4.2% per annum. Return on equity is forecast to be -64.3% in 3 years.
Key information
-2.1%
Earnings growth rate
4.2%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 81.8% |
| Future return on equity | -64.3% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9 | -213 | -183 | -217 | 5 |
| 12/31/2025 | N/A | -187 | -160 | -177 | 6 |
| 12/31/2024 | N/A | -173 | -160 | -159 | 6 |
| 9/30/2024 | 7 | -161 | -130 | -130 | N/A |
| 6/30/2024 | 7 | -157 | -146 | -146 | N/A |
| 3/31/2024 | 7 | -138 | -150 | -150 | N/A |
| 12/31/2023 | 7 | -151 | -161 | -160 | N/A |
| 9/30/2023 | N/A | -157 | -182 | -181 | N/A |
| 6/30/2023 | N/A | -173 | -183 | -183 | N/A |
| 3/31/2023 | N/A | -212 | -199 | -198 | N/A |
| 12/31/2022 | N/A | -216 | -202 | -201 | N/A |
| 9/30/2022 | N/A | -234 | -201 | -205 | N/A |
| 6/30/2022 | N/A | -220 | -195 | -199 | N/A |
| 3/31/2022 | N/A | -197 | -169 | -173 | N/A |
| 12/31/2021 | N/A | -381 | -136 | -136 | N/A |
| 9/30/2021 | N/A | -324 | -88 | -83 | N/A |
| 6/30/2021 | N/A | -286 | -56 | -52 | N/A |
| 3/31/2021 | N/A | -246 | -24 | -20 | N/A |
| 12/31/2020 | N/A | -11 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 260 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 260 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 260 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 260 is forecast to have no revenue next year.
High Growth Revenue: 260 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 260 is forecast to be unprofitable in 3 years.